Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Free Cash Flow: 2017-2024

Historic Free Cash Flow for Solid Biosciences (SLDB) over the last 8 years, with Dec 2024 value amounting to -$29.8 million.

  • Solid Biosciences' Free Cash Flow fell 42.73% to -$29.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$100.7 million, marking a year-over-year decrease of 5.19%. This contributed to the annual value of -$100.7 million for FY2024, which is 5.19% down from last year.
  • According to the latest figures from Q4 2024, Solid Biosciences' Free Cash Flow is -$29.8 million, which was down 25.82% from -$23.7 million recorded in Q3 2024.
  • In the past 5 years, Solid Biosciences' Free Cash Flow ranged from a high of $1.2 million in Q4 2020 and a low of -$35.3 million during Q4 2022.
  • Over the past 3 years, Solid Biosciences' median Free Cash Flow value was -$24.5 million (recorded in 2024), while the average stood at -$24.8 million.
  • As far as peak fluctuations go, Solid Biosciences' Free Cash Flow spiked by 105.70% in 2020, and later slumped by 1,826.86% in 2021.
  • Quarterly analysis of 5 years shows Solid Biosciences' Free Cash Flow stood at $1.2 million in 2020, then plummeted by 1,826.86% to -$21.5 million in 2021, then tumbled by 64.09% to -$35.3 million in 2022, then spiked by 40.82% to -$20.9 million in 2023, then crashed by 42.73% to -$29.8 million in 2024.
  • Its last three reported values are -$29.8 million in Q4 2024, -$23.7 million for Q3 2024, and -$21.8 million during Q2 2024.